Troxevasin, capsules 300 mg 50 pcs

Name: Troxevasin, capsules 300 mg 50 pcs
SKU: 108642
Availability: InStock

€17.47

EAN: 3800714202045 SKU: 108642 Categories: Cardiovascular, Medicine, Vein diseases

Description

Pharmacotherapeutic group: venotonizing and venoprotective agent

ATX code C05CA04

p> Pharmacological properties

Troxevasin contains at least 95% troxerutin. Troxerutin selectively accumulates in the endothelial layer of the vessels, penetrates deep into the subendothelial layer of the venous wall, creating higher concentrations there than in the surrounding tissues. It prevents damage to cell membranes caused by oxidative reactions. The antioxidant effect is manifested in the prevention and elimination of oxidative properties of oxygen, inhibition of lipid oxidation and protection of the vascular endothelium from the oxidative effects of hydroxyl radicals. Troxerutin reduces the increased permeability of capillaries and has venotonic effect. The cytoprotective effect results from inhibition of activation and adhesion of neutrophils, reduction of erythrocyte aggregation and increase of their resistance to deformation, reduction of release of inflammatory mediators. Troxerutin increases veno-arterial reflux and increases the time of repletion of veins, improves microcirculation and microvascular perfusion.

Troxerutin reduces pathological changes associated with venous insufficiency: swelling, pain, improves tissue trophism.

Interfering the permeability and resistance of capillary walls, troxerutin helps to slow the progression of diabetic retinopathy.

The effect of troxerutin on the rheological properties of the blood helps prevent the development of retinal vascular microthrombosis.

Pharmacokinetics

absorption

. After ingestion of the radioactively labeled drug, absorption of ¹⁴C-O-(β-hydroxyethyl)-rutoside in humans is about 10-15%. Maximum plasma concentrations (C_max) are reached within 1-9 hours. Within 120 hours, concentrations remain detectable; the decrease in concentration is bioexponential.

Distribution

The binding to plasma proteins is 27-29%, in the largest amounts it accumulates in the endothelium. It does not penetrate through the blood-brain barrier. It penetrates insignificantly through the placental barrier and is excreted in minimal quantities with breast milk.

Biotransformation

Metabolized mainly by o-glucuronidation in the liver.

Evolution

Extracted mainly through the intestine and to a lesser extent by the kidneys.

Indications
Indications
– Chronic venous insufficiency.
– Post-thrombotic syndrome.
– Trophic disorders in varicose veins and trophic ulcers.
– As adjunctive treatment after sclerotherapy of veins and removal of varicose knots.
– Hemorrhoids (pain, exudation, itching and bleeding).
– As adjunctive treatment of retinopathy in patients with diabetes mellitus, arterial hypertension and atherosclerosis.

Active ingredient
Active ingredient

Composition
Composition

How to take, the dosage
How to take, the dosage
To be taken orally with meals. Capsules should be swallowed whole with plenty of water.
In chronic venous insufficiency and its complications, in symptomatic treatment of hemorrhoids at the initial stage of treatment prescribe 1 capsule (300 mg) 2-3 times a day (600-900 mg) depending on the severity of symptoms. The effect usually develops within 2 weeks. Treatment is discontinued after symptoms and edema disappear.
If symptoms recur, treatment is resumed at the same dose or the dose is reduced to 1 capsule 2 times a day (600 mg).
The effect achieved lasts for at least 4 weeks. The average course of treatment is 3 to 4 weeks.
In diabetic retinopathy the drug is taken in a dose of 1800-3000 mg in 6-10 capsules (3-5 capsules (1800-3000 mg) twice daily). The average course of treatment is 3-4 weeks.
The need for longer treatment is determined after consultation with the doctor and individually.

Special Instructions
Special Instructions
In the treatment of superficial thrombophlebitis or deep vein thrombosis, the use of the drug does not exclude the need to prescribe anti-inflammatory and antithrombotic therapy.
Troxerutin is ineffective in edema due to concomitant liver, kidney and heart disease.
If during the period of using the drug, symptoms of the disease do not decrease or become more severe, the patient should immediately see a physician. There is not enough experience of using the drug in children under 18 years of age. If using the drug alone, do not exceed the maximum periods and recommended doses.
Influence on driving and operating machinery
The use of the drug has no effect on motor and mental reactions and does not prevent driving vehicles and other complex mechanisms.

Synopsis
Synopsis

Contraindications
Contraindications
– Pregnancy (1st trimester).
– Gastric and duodenal ulcer.
– Chronic gastritis in the acute phase.
– Children under 18 years of age (experience of clinical use is insufficient).
– Breast-feeding.
– Rare hereditary intolerance to galactose, lactase deficiency, glucose-galactose malabsorption syndrome.
With caution
– In renal failure (with prolonged use).
– Pregnancy (II and III trimesters).

Side effects
Side effects
The incidence of adverse reactions is given according to the WHO classification: very common (â¥1/10), common (â¥1/100, Ë1/10), infrequent (â¥1/1000, Ë1/100), rare (â¥1/10000, Ë1/1000), very rare (Ë1/10000), frequency unknown (cannot be estimated based on available data).
Disorders immune system: very rarely – anaphylactic shock, anaphylactoid reactions, hypersensitivity reactions (eg, skin rash).
Disorders with the nervous system: very rarely – headache, dizziness.
Disorders vascular disorders: very rarely – hyperemia (“tides” of blood), ecchymosis.
Gastrointestinal tract disorders: very rarely – nausea, pain and discomfort in the stomach, dyspepsia, flatulence, diarrhea, gastrointestinal erosive ulcers.
Skin and subcutaneous tissue disorders: sometimes – itching, rash, urticaria.
Others: very rarely – feeling of fatigue.
In case of adverse reactions, consult a doctor.

Overdose
Overdose

Pregnancy use
Pregnancy use

Similarities
Similarities

Additional information
Weight 0.039 kg
Shelf life
5 years
Conditions of storage
In a dry, light-protected place at a temperature not exceeding 25 °C
Manufacturer
Balkanpharma – Troyan AD, Bulgaria
Medication form
capsules
Brand
Balkanpharma – Troyan AD